Last reviewed · How we verify
Tapentadol ER 250-mg TRF tablet — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Tapentadol ER 250-mg TRF tablet (Tapentadol ER 250-mg TRF tablet) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tapentadol ER 250-mg TRF tablet TARGET | Tapentadol ER 250-mg TRF tablet | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tapentadol ER 250-mg TRF tablet CI watch — RSS
- Tapentadol ER 250-mg TRF tablet CI watch — Atom
- Tapentadol ER 250-mg TRF tablet CI watch — JSON
- Tapentadol ER 250-mg TRF tablet alone — RSS
Cite this brief
Drug Landscape (2026). Tapentadol ER 250-mg TRF tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/tapentadol-er-250-mg-trf-tablet. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab